IL17A and pustular psoriasis: In our patient cohort, all patients were treated with biologic agents including those targeting TNF-α, IL-17 and IL-23 that might obtain beneficial effects on the treatment of pustular psoriasis (27, 28), though only a few of them own the labeled indication for GPP (namely brodalumab, ixekizumab, and risankizumab in Japan).